Markt oder Branche auswählen:
| Unternehmen / Aktien | News 24 h | News 7 T | Kurs | ||
|---|---|---|---|---|---|
| BIONTECH | 4 | 13 | +0,06 % | ||
| DISC MEDICINE | 3 | 7 | -0,57 % | ||
| NURIX THERAPEUTICS | 3 | 4 | +0,44 % | ||
| VERTEX PHARMACEUTICALS | 2 | 5 | +0,41 % | ||
| BEAM THERAPEUTICS | 2 | - | -6,30 % | ||
| AMGEN | 1 | 27 | -0,44 % | ||
| ARVINAS | 1 | 6 | +1,87 % | ||
| GILEAD SCIENCES | 1 | 5 | -0,06 % | ||
| VIATRIS | 1 | 2 | +0,32 % | ||
| ORIC PHARMACEUTICALS | 1 | 2 | +6,88 % |
- 24 h
- 7 Tage
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Sa | TScan Therapeutics, Inc.: TScan Therapeutics Announces Positive Updated Data from the ALLOHA Phase 1 Heme Trial at the 67th American Society of Hematology Annual Meeting and Exposition | 1 | GlobeNewswire (USA) | ||
| Sa | BioNTech SE: BioNTech and OncoC4 Announce Clinically Meaningful Overall Survival Benefit for Selective Treg Modulator Gotistobart in Patients with Previously Treated Squamous Non-Small Cell Lung Cancer | 314 | GlobeNewswire (Europe) | Selective Treg modulator gotistobart (BNT316/ONC-392) showed a reduction in the risk of death by more than half compared to standard of care chemotherapy and a manageable safety profile in the first... ► Artikel lesen | |
| Sa | BioNTech SE: BioNTechs und OncoC4s selektiver Treg-Modulatorkandidat Gotistobart erzielte klinisch relevanten Gesamtüberlebensvorteil bei Patientinnen und Patienten mit zuvor behandeltem Plattenepithelkarzinom der Lunge | 821 | GlobeNewswire (Deutschland) | Der selektive Treg-Modulatorkandidat Gotistobart (BNT316/ONC-392) zeigte eine Verringerung des Sterberisikos um mehr als die Hälfte im Vergleich zur Standard-Chemotherapie sowie ein kontrollierbares... ► Artikel lesen | |
| Sa | BMO Capital Lifts Amgen (AMGN) Price Target as MariTide Outlook Strengthens | 7 | Insider Monkey | ||
| Sa | Gilead-Tochter Kite meldet vielversprechende Ergebnisse für CAR-T-Zelltherapien bei Lymphomen | 2 | Investing.com Deutsch | ||
| Sa | Legend Biotech USA Inc.: Legend Biotech Highlights New CARVYKTI Data in Multiple Myeloma and First-in-Human Results from Novel CAR-T Platform in Non-Hodgkin Lymphoma at ASH 2025 | 3 | GlobeNewswire (USA) | ||
| Sa | Genmab Reports Promising Clinical Trial Results For Fixed-Duration Epcoritamab In Lymphoma | 263 | AFX News | TOKYO (dpa-AFX) - Genmab A/S (GMAB) announced updated findings from multiple ongoing clinical trials evaluating epcoritamab-bysp, a subcutaneously administered, T-cell engaging antibody.The... ► Artikel lesen | |
| Sa | Wochenend-Update: Biontech-Aktie im Fokus - was Anleger jetzt wissen müssen! | Hebelschein-Spekulant | |||
| Sa | Nurix reports 83% response rate for bexobrutideg in CLL patients | 1 | Investing.com | ||
| Sa | Nurix: Bexobrutideg erzielt 83 % Ansprechrate bei Leukämie-Patienten | 4 | Investing.com Deutsch | ||
| Sa | Viatris To Sell Equity Stake In Biocon Biologics To Biocon For $815 Mln | 350 | AFX News | NEW DELHI (dpa-AFX) - Viatris Inc. (VTRS) announced that it has entered into definitive agreements with Biocon Limited for the sale of its equity stake in Biocon Biologics Limited. Under the... ► Artikel lesen | |
| Sa | Cogent Biosciences, Inc.: Cogent Biosciences Presents Full SUMMIT Results of Bezuclastinib in Patients with NonAdvanced Systemic Mastocytosis (NonAdvSM) at the 67th Annual Meeting of the American Society of Hematology (ASH) | 2 | GlobeNewswire (USA) | ||
| Sa | Genmab A/S: Genmab Announces Data From Multiple Clinical Trials Showing Treatment with Fixed-Duration Epcoritamab Led to Remissions in First-Line Diffuse Large B-Cell Lymphoma (DLBCL) and Follicular Lymphoma (FL) | 6 | GlobeNewswire (USA) | ||
| Sa | Nurix Therapeutics, Inc.: Nurix Therapeutics Presents New Data Demonstrating Durable, Deepening Responses in Phase 1 Trial of Bexobrutideg (NX-5948) in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) at the 67th American ... | 2 | GlobeNewswire (USA) | ||
| Sa | Vertex Presents New CASGEVY Data Highlighting Benefits In Children Ages 5-11 | 335 | AFX News | CAMBRIDGE (MASSACHUSETTS) (dpa-AFX) - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced new data from pivotal studies of CASGEVY (exagamglogene autotemcel), demonstrating the transformative... ► Artikel lesen | |
| Sa | Adaptive Biotechnologies Showcases Leadership in Hematology-Oncology MRD with New clonoSEQ Data Driving Treatment Interventions at 2025 ASH Annual Meeting | 2 | GlobeNewswire (USA) | ||
| Sa | Beam Therapeutics: Positive Studiendaten zur Sichelzelltherapie treiben Aktie an | 6 | Investing.com Deutsch | ||
| Sa | Disc Medicine meldet positive Studiendaten zu Anämie-Medikament DISC-0974 | 2 | Investing.com Deutsch | ||
| Sa | Disc Medicine reports positive data from DISC-0974 anemia trial | 1 | Investing.com | ||
| Sa | Arvinas Inc.: Arvinas Presents Preclinical Data Supporting Mechanistic Synergies and Enhanced Antitumor Activity with the Combination of ARV-393 and Glofitamab at the 2025 American Society of Hematology Annual Meeting and Exposition | 4 | GlobeNewswire (USA) |
1 2 3 4 5 Weiter >>
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .